GEHC vs. HAE: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • 10 hours ago

Blood Plasma Name Hits Highs On FDA Approval As Earnings Loom

Haemonetics provides tools for blood products management such as plasma collection and providing systems, training and services for blood collection.

Investors Business Daily • Oct 28, 2026

Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts

Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds into Royal Caribbean Group. Middleby completed the spin-off of Midera Food Processing, announced plans to exit its underperforming business, and continued buying back shares.

Seeking Alpha • Oct 28, 2026

All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Oct 27, 2026

Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.

Seeking Alpha • Oct 27, 2026

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

Zacks Investment Research • Oct 20, 2026

Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bore closure devices for structural heart and endovascular procedures in the U.S., following the company's acquisition of Vivasure Medical Limited in January 2026.

PRNewsWire • Oct 19, 2026

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.

Zacks Investment Research • Oct 16, 2026

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.

Zacks Investment Research • Oct 15, 2026

Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Oct 13, 2026